Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To describe costs, healthcare resource utilization, and adherence of US patients receiving human regular U-500 insulin (U-500R), compared to patients receiving high-dose (>200 units/day) U-100 insulins (U-100) by subcutaneous injection for the treatment of diabetes. METHODS: A retrospective analysis of data from Thomson Reuters MarketScan Research Databases (7/1/2008 to 12/31/2010). Difference-in-differences analyses were conducted on cost (medical, pharmacy, and overall costs) and on healthcare resource utilization variables (overall, diabetes-related, and non-diabetes-related medical visits). Adherence rates to the index insulins were assessed by proportion of days covered (PDC). RESULTS: Seven hundred and eleven (19%) patients in the U-500R cohort and 1508 (6%) patients in the U-100 cohort met selection criteria. Propensity score matching resulted in 684 matched pairs. Mean change in annualized pharmacy costs was in favor of the U-500R vs the U-100 cohort (-$1258 vs $3345, a difference of -$4603, p < 0.0001). Mean overall cost increase in the U-500R vs the U-100 cohort was also lower ($1999 vs $9104, a difference of -$7105, p = 0.005). The proportion of patients with at least one coded hypoglycemic event during the 12-month post-index period was higher in the U-500R vs the U-100 cohort (17.1% vs 11.7%, p < 0.005), but neither hypoglycemia rate (2.73 vs 2.90 events per person) nor hypoglycemia-specific costs (mean $1669 vs $1543) were significantly different. No significant differences were noted between cohorts for change (post-pre) in any resource utilization category. PDC was greater in the U-500R vs the U-100 cohort (65.2% vs 39.5%, p < 0.0001). LIMITATIONS: Claims data are not as accurate as empirical evaluation by a clinician. Glycemic control data were not available for this analysis. CONCLUSIONS: In patients requiring high-dose insulin, treatment with U-500R vs high-dose U-100 insulins is associated with significant decreases in pharmacy and overall costs, slightly higher hypoglycemia incidence, no difference in hypoglycemia-specific costs or in resource utilization, and better adherence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C. (2011) · Pharmaceutical Statistics · doi:10.1002/pst.433 · Cited by 3,949
Design of Observational Studies
Rosenbaum, P. R. (2010) · Springer Series in Statistics · doi:10.1007/978-1-4419-1213-8 · Cited by 1,150
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
de la Peña, A., Riddle, M., Morrow, L. A., Jiang, H. H., Linnebjerg, H., Scott, A., Win, K. M., Hompesch, M., Mace, K. F., Jacobson, J. G., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0721 · Cited by 125
Self-citationClinical use of U-500 regular insulin: Review and meta-analysis
Reutrakul, S., Wroblewski, K., & Brown, R. L. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600229 · Cited by 94 · cited 2×
“Considering the low number of clinical case reports/series (310 multiple daily dosed U-500R patients in the most recent review/meta-analysis by Reutrakul et al.6) and the fact that there have been no randomized clinical trials of U-500R, the sample sizes in this study were remarkably large.”
Background
Cited by
The evolution of insulin and how it informs therapy and treatment choices
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa015 · Cited by 237
A Systematic Review of Insulin Adherence Measures in Patients with Diabetes
Stolpe, S., Kroes, M. A., Webb, N., & Wisniewski, T. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.11.1224 · Cited by 77
“…aimed to describe the level of adherence to high-dose regimens, calculated PDC based on the proportion of days for which > 200 units/day of insulin were available (PDC200) in Eby et al. (2013)46 and the proportion of days for which ≥ 150 units/day of insulin were available (PDC150) in Eby et al.…”
MethodHood, R. C., Arakaki, R. F., Wysham, C., Li, Y. G., Settles, J. A., & Jackson, J. A. (2015) · Endocrine Practice · doi:10.4158/ep15612.or · Cited by 61
Self-citationMitchell, B. D., He, X., Sturdy, I. M., Cagle, A. P., & Settles, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15831.or · Cited by 46
Adherence to insulin treatment in diabetes: can it be improved?糖尿病患者使用胰岛素治疗的依从性:它能够得到改善吗?
Doggrell, S. A., & Chan, V. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12212 · Cited by 29
Metadata
- Authors
- Eby, E. L., Wang, P., Curtis, B. H., Xie, J., Haldane, D. C., Idris, I., Peters, A. L., Hood, R. C., & Jackson, J. A.
- Venue
- Journal of Medical Economics
- Publisher
- Informa Healthcare
- Published
- 2013-02-12
- Volume
- 16
- Issue
- 4
- Pages
- 529-538
- ISSN
- 1369-6998 (ISSN-L)
- 1941-837X
- OpenAlex
- W2088253528
- Cited by
- 31
- References
- 5
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. https://app.cochat.ai/papers/10.3111/13696998.2013.772059
- The paper
- Eby, E. L., Wang, P., Curtis, B. H., Xie, J., Haldane, D. C., Idris, I., Peters, A. L., Hood, R. C., & Jackson, J. A. (2013). Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. Journal of Medical Economics. https://doi.org/10.3111/13696998.2013.772059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.